An accredited satellite symposium held at the 2022 HFSA Annual Scientific Meeting of the Heart Failure Society of America.

Expert Perspectives on the Evolving Treatment Paradigm in **HEART FAILURE MANAGEMENT**

Meetings Held in: NATIONAL HARBOR ROOMS 10-11

Sunday, October 2, 2022

In-Person + Live Streaming Satellite Symposium Registration 5:15 PM - 5:30 PM EDT Scientific Session 5:30 PM - 7:00 PM EDT Gaylord National Resort & Convention Center

This symposium brings together renowned heart failure (HF) experts to discuss both emerging clinical data for key therapeutic classes used to treat HF and current and potential future clinical applications for these agents. The focus will be newer pharmacotherapies that target the pathophysiologic pathways of HF and address unmet needs. The clinical expert faculty will also review and provide context regarding updated clinical guideline recommendations to best prepare clinicians on the front lines of HF care and, ultimately, to improve patient outcomes.

LEARNING OBJECTIVES

- Identify diagnostic strategies for HF with reduced ejection fraction (HFrEF) based on recent guidelines
- Apply evidence-based guidelines for treatment selection for HFrEF and its comorbidities
- Outline the mechanisms of action of emerging therapies for HFrEF
- Differentiate clinical trial evidence for emerging therapies to manage HFrE

PROGRAM CHAIR



Andrew Sauer, MD Associate Professor Saint Luke's Health System Kansas City, MO

FACULTY

Justin Ezekowitz, MBBCh, MSc Ashley Tringale, CNP Professor, Department of Medicine University of Alberta

Aferdita Spahillari, MD Assistant Professor Massachusetts General Hospital Massachusetts General Hospital Boston, MA



gotoper.com/HF22

Accreditation/Credit Designation

1.5 credit/contact hours for physicians and nurses

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc & Eli Lilly and Company Alliance.



